LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

Search

BioCryst Pharmaceuticals Inc

Fechado

SetorSaúde

7.62 -0.13

Visão Geral

Variação de preço das ações

24h

Atual

Mín

7.55

Máximo

7.62

Indicadores-chave

By Trading Economics

Rendimento

5.1M

5.1M

Vendas

18M

163M

Margem de lucro

3.113

Funcionários

580

EBITDA

7.2M

28M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+129.36% upside

Dividendos

By Dow Jones

Próximos Ganhos

3 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-172M

1.7B

Abertura anterior

7.75

Fecho anterior

7.62

Sentimento de Notícias

By Acuity

50%

50%

132 / 371 Ranking em Healthcare

BioCryst Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

26 de set. de 2025, 18:25 UTC

Grandes Movimentos do Mercado

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

27 de set. de 2025, 07:00 UTC

Ganhos

This Water Stock Is Dehydrated. What Could Bring It Back. -- Barrons.com

27 de set. de 2025, 04:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

26 de set. de 2025, 21:56 UTC

Aquisições, Fusões, Aquisições de Empresas

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

26 de set. de 2025, 20:54 UTC

Ganhos

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

26 de set. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 de set. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

26 de set. de 2025, 20:27 UTC

Aquisições, Fusões, Aquisições de Empresas

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 de set. de 2025, 20:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

26 de set. de 2025, 19:54 UTC

Conversa de Mercado

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

26 de set. de 2025, 19:53 UTC

Aquisições, Fusões, Aquisições de Empresas

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 de set. de 2025, 19:40 UTC

Ganhos

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

26 de set. de 2025, 19:24 UTC

Conversa de Mercado

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

26 de set. de 2025, 19:17 UTC

Conversa de Mercado

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

26 de set. de 2025, 19:15 UTC

Conversa de Mercado

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

26 de set. de 2025, 19:03 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

26 de set. de 2025, 19:03 UTC

Conversa de Mercado

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

26 de set. de 2025, 18:50 UTC

Conversa de Mercado
Ganhos

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

26 de set. de 2025, 18:36 UTC

Conversa de Mercado

Silver Closes Out Week With Strong Surge -- Market Talk

26 de set. de 2025, 18:02 UTC

Aquisições, Fusões, Aquisições de Empresas

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

26 de set. de 2025, 18:02 UTC

Aquisições, Fusões, Aquisições de Empresas

ING: Global Development Hasn't Received All Necessary Approvals >ING

26 de set. de 2025, 18:02 UTC

Aquisições, Fusões, Aquisições de Empresas

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

26 de set. de 2025, 17:54 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

26 de set. de 2025, 16:56 UTC

Conversa de Mercado
Ganhos

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

26 de set. de 2025, 16:41 UTC

Conversa de Mercado
Ganhos

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

26 de set. de 2025, 16:26 UTC

Ganhos

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

26 de set. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

26 de set. de 2025, 16:12 UTC

Conversa de Mercado

Nike Stock Seen With Limited Upside -- Market Talk

26 de set. de 2025, 15:59 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

26 de set. de 2025, 15:59 UTC

Conversa de Mercado

Nike Seen Showing Progress in Turnaround -- Market Talk

Comparação entre Pares

Variação de preço

BioCryst Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

129.36% parte superior

Previsão para 12 meses

Média 17.5 USD  129.36%

Máximo 30 USD

Mínimo 12 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para BioCryst Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

6

Comprar

0

Manter

0

Vender

Sentimento

By Acuity

132 / 371 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
help-icon Live chat